Related Experiment Videos
Male-specific modification of human CD52.
S Schröter1, P Derr, H S Conradt
1Institute for Hormone, University of Hamburg, Grandweg 64, D-22529 Hamburg, Germany.
The Journal of Biological Chemistry
|October 9, 1999
Summary
CD52, a molecule found on lymphocytes and sperm, exhibits distinct structural differences in the male genital tract. These variations in its glycan and lipid anchor may influence its function and potential as a therapeutic target.
Area of Science:
- Biochemistry
- Immunology
- Glycobiology
Background:
- CD52 is a glycopeptide expressed on lymphocytes and in the male genital tract.
- In the male genital tract, CD52 is found on sperm and in seminal plasma, suggesting a role in sperm function and interaction.
- Previous studies indicated cell type-specific modifications of CD52.
Purpose of the Study:
- To perform a detailed structural analysis of CD52 purified from seminal plasma.
- To compare the structure of male genital tract CD52 with the lymphocyte form.
- To investigate the potential of sperm surface CD52 as a target for antibodies.
Main Methods:
- Purification of CD52 from seminal plasma.
- Detailed structural analysis, including N-glycan and lipid anchor characterization.
- Western blot analyses to assess cell type-specific modifications.
Main Results:
- Male genital tract CD52 predominantly features 2-inositol palmitoylation and a sn-1-alkyl-2-lyso-glycerol anchor, differing from the diacylated anchor in lymphocytes.
- N-glycans are highly charged, sialylated, and contain lactosamine repeats, with some branching and peripheral fucose.
- Significant structural differences were confirmed between lymphocyte and male genital tract CD52.
Conclusions:
- Male genital tract CD52 possesses unique N-linked glycans and a distinct lipid anchor compared to the lymphocyte form.
- These structural variations highlight the specialized nature of CD52 in the male reproductive system.
- The distinct structure of sperm CD52 warrants further investigation for its role in fertility and potential therapeutic targeting.